3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
254
Breast
21
Tumor-Agnostic
11
Gastrointestinal
11
Thoracic
10
Gynecologic
7
Other solid neoplasm
5
Lymphoid
4
Head & Neck
4
Dermatologic
4
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Prostatic Neoplasms
1
Liposarcoma
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Radiotherapy
215
Cyclophosphamide
210
Doxorubicin
207
Temozolomide
181
Ifosfamide
121
Filgrastim
111
Etoposide
101
Imatinib Mesylate
99
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Irinotecan
79
Magnetic Resonance Spectroscopy
78
pembrolizumab
75
Radiation
66
Carboplatin
65
pazopanib
60
Methotrexate
60
Nivolumab
58
Cisplatin
58
fludarabine phosphate
56
Peripheral Blood Stem Cell Transplantation
56
Specimen Handling
53
Docetaxel
50
Busulfan
48
Trabectedin
47
Biopsy
47
Melphalan
46
Surgical Procedures, Operative
44
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
enzalutamide
×
Sarcoma
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled